Club of Amsterdam, Future, Think Tank ..
Menu

Club of Amsterdam Journal
Free Subscription
click here





































 

 

 


 

 

 

 


 


 

 


 

 



 


 

 


 

 

 

 



 




 






 


 

 

 

 


 

 

 


 

 

 

 


 

 

 


 

 


 

 

 

 

 

 

 


 

 

 

 

 

 


 

 



 

 

 

 

 

 


 

 

 



 

 

 

 

 

 


 

 

 



 

 

 

 

 

 


 

 

 

 

 

 


 

 

 

 

 


 

 

 

 


 

 

 

 

 

 

 

 


 

 

 

 


 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 





keyword search

Biopharmaceutical Outsourcing - Moving to Centerstage
Average reader rating: 0  
by Evalueserve Life Sciences

Biopharmaceuticals is the most upcoming segment of the pharmaceutical industry due to the evolution of biotechnology. This has resulted in highly efficacious products that aim at providing cures for life-threatening, difficult ailments, which have been difficult (well nigh impossible!) to treat. This industry is keeping its nose to the grindstone to reach the pinnacle. Certain factors, like increasing costs, complex regulatory issues, high prices, tremendous competition, etc., are forcing companies to improve their operational efficiency and productivity. Outsourcing has become a strategic imperative for companies in their quest to improve their efficiency and productivity.

Figure 1: Outsourcing in Biopharmaceutical Market (USD billion) - (2000-2008)



According to Figure 1 the biopharmaceutical market is forecasted to growth at a CAGR of 10 percent reaching USD 58.6 billion in 2008 from USD 36.5 billion in 2003. Outsourcing in this sector, however, has been increasing at a rate of 20 percent per annum. The coming years will witness an increasing proportion of biopharmaceutical activities being outsourced.

Outsourcing or Offshoring - Does It Really Matter?

The conventional idea of offshoring processes to low-cost Asian countries is not the only way out for biopharmaceutical outsourcing. Outsourcing in biopharmaceuticals has crossed the Rubicon as far as cost reduction is concerned. Companies now have a vision that goes beyond cost cutting. In fact, the majority of the top service providers, like Boehringer Ingelheim, Lonza Custom Manufacturing, etc., are based in the United States. However, there are emerging opportunities in Asian countries, which is driving offshoring of biopharmaceuticals to these destinations. Biocon in Bangalore, India, has announced that it will manufacture Bristol-Myers Squibb's (New York, NY, USA) recombinant insulin product. In the area of clinical trials, the Biopharmaceutical Manufacturing Technology Center (Singapore), a part of the Bio processing Technology Institute, has opened a pilot-scale facility to produce materials through Phase II clinical trials.

[...]




You can download the full report as a *.pdf: click here

 

 

Summit for the Future - Life Sciences


You can find more about Summit for the Future in the Books, Articles and Links section.

 










Rated 0 by other users. What do you think? [rate this article]

Copyright 2002-2018 Club of Amsterdam. All rights reserved.    Contact     Privacy statement    Cancellation Policy